A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
GB491-005 is a multicenter, open-label, phase Ib Clinical Trial study to evaluate the safety,
pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of
GB491 in combination with Letrozole in Previously Untreated Patients with HR-positive,
HER2-negative Advanced Breast Cancer